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ABSTRACT  
Primary testicular lymphoma (PTL) represents 1-2% of all types of non-Hodgkin lymphomas (NHLs) and 1-10% of testicular ne-
oplasms. Up to the best of my knowledge, this is the first case of PTL of the diffuse large B-cell lymphoma (DLBCL) in a 60-year-
old man presented with a painless mass in the left testis as revealed by physical examination in a tertiary care hospital in Al-
Madinah Al-Munawarah in the western region of the Kingdom of Saudi Arabia (KSA). Radiological examination revealed a large 
well-defined heterogeneous predominantly hypo-echoic mass with increased vascularity in the upper portion of the testis. On the 
other hand, histopathological examination revealed a tumor involving the whole left testis, which was large (measuring 6 × 3.5 × 
3.3 cm), solid and dark red with focal areas of hemorrhage and epididymal infiltration. Immunohistochemistry showed positivity 
of leucocyte common antigen (LCA), pan B-cell marker (CD20) and negativity of pan T-cell marker (CD3). Other immunohisto-
chemical markers such as CD10, placental alkaline phosphatase (PLAP), cytokeratin, vimentin, desmin and S100 protein were 
also negative. However, there was a marked expression of Ki67 and Bcl2 markers. Accordingly, the diagnosis of DLBCL was estab-
lished. The tumor was classified as stage I according to the Ann Arbor system. The case was treated by orchiectomy followed by 
prophylactic anthracycline-based chemotherapy and irradiation of the contralateral testis and central nervous system. 
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1. Introduction 
Primary testicular lymphoma (PTL) represents 1-
2% of all types of non-Hodgkin lymphomas 
(NHLs) and 1-10% of testicular neoplasms affect-
ing the elderly with a poor prognosis.(1) The most 
common histological variant of PTL is the diffuse 
large B-cell lymphoma (DLBCL).(1) Although 
DLBCL is the most common histopathological type 
of PTL, secondary infiltration of the testis, espe-
cially in high-grade Burkitt's lymphoma, is more 
prevalent.(2) The most common clinical presenta-
tion of PTL is a unilateral testicular mass.(2) No 
case report or case series of PTL have been re-
ported from the western region of the Kingdom of 
Saudi Arabia (KSA), and the present case is the 
first PTL of the DLBCL type to be reported from 
the western region of the KSA. 
 
2. Case presentation 
A 60-year-old man presented at the Urology De-
partment of a tertiary care hospital in Al-Madinah 
Al-Munawarah in the western region of KSA in Oc-
tober 2017. He complained of a painless swelling 
in his left testis for three weeks, which was re-
vealed as a firm mass by physical examination. 
Besides the absence of systemic symptoms, nei-
ther regional/generalized lymphadenopathy nor 
hepatosplenomegaly was detected. In addition, 
head, neck, chest and abdomen investigations 
were normal. Hematological investigations re-
vealed a hemoglobin level of 14.4 g/dl, a total leu-
cocyte count of 9.8×109/L, a platelet count of 
250×109/L. Biochemical investigations revealed 
normal renal function tests and liver enzyme pro-
files Ultrasonography revealed a large (2.7 × 1.7 
cm) well-defined heterogeneous and predomi-
nantly hypo-echoic mass with increased vasculari-
ty in the upper portion of the left testis. Left testis 
measured 4.8 × 2.8 × 2.4 cm, while the right testis 
was normal except for a small epididymal cyst 
measuring 1.5 × 0.8 cm. Computed tomography 
scan of the abdomen and thorax revealed no ab-
normalities.  
After undergoing left inguinal orchiectomy, 
histopathological examination revealed a tumor 
involving the whole left testis. The tumor was sol-
id and dark red with focal areas of hemorrhage 
and measuring 6 × 3.5 × 3.3 cm. The tumor was 
infiltrating the epididymis but without infiltration 
of the tunica albuginea or tunica vaginalis. The 
relevant histopathological microphotographs are 
shown in Figure 1 (A-C). 
 
Figure 1. Testicular invasion by large B-cell lymphoma at different magnifications: (A) 100x, 100 μm scale bar;  (B) 200x, 50 μm 
scale bar; (C) 400x, 25 μm scale bar. 
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Immunohistochemistry showed positivity of 
leucocyte common antigen (LCA), pan B-cell 
marker (CD20) and negativity of pan T-cell mark-
er (CD3). Other immunohistochemical markers 
such as CD10, placental alkaline phosphatase 
(PLAP), cytokeratin, vimentin, desmin and S100 
protein were also negative. However, there was a 
marked expression of Ki67 and Bcl2 markers. Ac-
cordingly, the diagnosis of DLBCL was established. 
The tumor was classified as stage I according to 
the Ann Arbor system.(3) 
 
3. Discussion 
Up to the best of my knowledge, no individual case 
or case series of PTL have been reported from the 
western region of KSA. However, only a single 
case of PTL was documented out of 19 cases of 
testicular cancers among patients from Dammam 
in the eastern region of KSA and presented at the 
22nd Saudi Urological Conference in March 2010.(4) 
PTL represents up to 10% of all testicular 
cancers.(1, 5) Moreover, DLBCL is the most common 
type of PTL, representing 69–90% of PTL.(5) Ap-
proximately 60% and 305 of patients are in stage I 
and II, respectively, and bilateral testicular in-
volvement can be found in approximately 35% of 
cases.(5) In accordance with the published litera-
ture, the present case was in the seventh decade 
of life and presented with unilateral painless tes-
ticular mass but without B symptoms.(6)  
According to the Ann Arbor staging system,(3) 
the PTL of the present case is classified as stage I. 
Post-operatively, the patient received anthracy-
cline-based chemotherapy and irradiation of the 
contralateral testis and central nervous system. 
Complete remission was achieved with no serious 
side effects of the chemoradiotherapy. The patient 
was on follow-up with no recurrence or relapse 
after three years. Therefore, the same pattern of 
treatment was given to the patient, where the pa-
tient’s follow-up revealed no recurrence or re-
lapse. 
No standard treatment modality exists for PTL 
because it is a rare incidence. However, R-CHOP 
(rituximab, cyclophosphamide, doxorubicin, vin-
cristine and prednisone) are used for the treat-
ment of stage I and II PTL, and prophylactic scro-
tal radiotherapy together with systemic chemo-
therapy are performed after orchiectomy.(7) Dis-
tant relapses often occur in most patients with 
stage I PTL if adjuvant therapy is not administered 
after orchiectomy. In stage II, radiotherapy of lo-
calized lymph nodes can prevent nodal relapses. 
In stages III-IV, systemic and intrathecal chemo-
therapy as well as scrotal radiotherapy are per-
formed.(8) 
 
4. Conclusions  
This is the first report of DLBCL type of PTL from 
Al-Madinah Al-Munawarah in the western region 
of KSA. PTL is a rare tumor of the testes but can be 
the most common testicular tumor in the elderly. 
Although PTL is a disease with a poor prognosis, 
no recurrence or relapse was observed in the pre-
sent case on follow-up for more than three years. 
Because of the rare incidence of PTL besides its 
different development and progress in compari-
son to germ-cell testicular cancers, it is difficult to 
determine the treatment procedures to be applied 
after orchiectomy. Therefore, PTL should be con-
sidered as a manifestation of systemic diseases of 
the testis. Moreover, contralateral testis and re-
lapse in the central nervous system should always 
be considered. PTL should also be considered in 
patients presenting with a painless mass in the 
testis, where a joint action should be undertaken 
by the urologist, pathologist, and oncologist inves-
tigating the case. We have reported the first case 
of PTL from Al-Madinah Al-Munawarah in the 
western region of KSA.  
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